Navigation Links
WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Date:3/12/2008

ontinuity of operations and services to AppTec's existing client base and will help expedite the integration of our complementary service lines.

2008 Guidance

We estimate that our 2008 consolidated revenues will range from $280 million to $300 million.

Conference Call

Following the earnings announcement, WuXi PharmaTech's senior management will host a conference call at 9:00 am (Eastern) / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, March 13, 2008 to discuss its fourth quarter and full year 2007 financial results and recent business activities. The conference call may be accessed by calling (US) +1-888-596-2633/ (UK) +0808-101-1402 / (HK) +800-965-503/ (China, Northern Region) +10-800-714-0970/ (China, Southern Region) +10-800-140-0945. A telephone replay will be available shortly after the call until April 12, 2008 at (US) +1-888-203-1112/ (UK) +0808-101-1153 / (HK) +800-901-108 / (China, Northern Region) +1-719-457- 0820/ (China, Southern Region) +10-800-140-1178, Passcode: 2224172.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .

About WuXi PharmaTech

WuXi PharmaTech, headquartered in Shanghai, China, is the leading global pharmaceutical, biotechnology and medical device R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory, research manufacturing, biologics testing and manufacturing services throughout the drug and medical device research and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device research and development by providing cost-effective and efficient outsourcin
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
2. WuXi PharmaTech Completes Acquisition of AppTec
3. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
4. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
5. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
6. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
7. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
8. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
9. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
10. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
11. WuXi PharmaTech Announces Second Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... is available in German . , Whether it,s CD...ID tags (Radio Frequency Identification) are incre... make it possible to label objects or goods and id...appropriate scanner can read and process the data ...d to goods under production conditions of up to 10...
(Date:11/24/2009)... The New York investment bank KTA Capita...s agreed an AU$6.7 mil convertible note private pl...ivate placement was arranged by KTA Capital as Neu... New York (PRWEB) November 23... KTA Capital, LLC ("KTA Capital") has an...
(Date:11/24/2009)...IK,Iceland,November24/PRNewswire-FirstCall/--deCOD...hasreceivednoticefrom,theNasdaqStockMarketthattrad...vember30,2009andaForm25-NSEwillbefiledwiththe,Secu...scommonstock,fromlistingonNasdaq,unlessthecompanyf....Thecompanyhasfiledsuchanappeal,which,willstaythes...
(Date:11/24/2009)...IK,Iceland,November24/PRNewswire-FirstCall/--deCOD...rovalofallofits,"firstday"motionsbytheU.S.Bankrupt...rt").deCODElastweekfiledavoluntarypetitionfor,reli...hthe,BankruptcyCourt. , TheordersissuedbytheB...tsbusinessduringtheChapter11proceedings.Inparticul...
Breaking Biology Technology:Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...y announces implementation of Kingdee enterprise a...perations , , TUSTIN, Calif., Jan. 29 AMDL, Inc.... pharmaceutical company with operations in China a...ate-of-the-art, westernized enterprise accounting ..., , Developed by China-based Kingdee Internatio...
...ies to Collaborate on Next Generation Laboratory I...ss., Jan. 29 Cantimer, Inc. and Advanced Instrume...struments Inc. has made a $1 Million equity invest...nced their intention to collaborate on the develop... for osmolality measurement, incorporating Cantime...
...y will proceed with clinical trials of first-in-cl...SHORES, Calif., Jan. 29 Omnitura Therapeutics Inc... into a $24 million private placement agreement wi...ancing, investments will be made in three tranches...ore December 31, 2009 and $8 million before Decemb...
Other Biology Technology:AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 2AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 3AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 4Advanced Instruments Makes Strategic Investment in Cantimer, Inc. 2Omnitura Therapeutics Announces Private Placement Financing 2
(Date:11/23/2009)..., Mass. November 23, 2009 Applied mathematicians...osta lancifolia ), a characteristic long leaf with...ipples along the edges. The simple cause of the li...om bending during differential growthwas revealed ...oam ribbons. , Haiyi Liang, a postdoctoral stude...
(Date:11/23/2009).... -- More than 160 participants gathered this week...TURES INITIATIVE conference. This year,s topic, "S...gineers, and medical researchers to explore the en...ng the emerging field of synthetic biology. , Bo... Princeton University and this year,s conference c...
(Date:11/23/2009)...- The only swine vaccine available for the H1N1 vi...ed with the virus. The vaccination marks the first...sed with the pandemic flu., Iowa State Universit...loped the vaccine this summer and has been shippin...sas and Illinois for several weeks., The latest ...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 14261 1Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 14261 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 14261 3Bionovo to Present on Novel Female Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society 14259 1Bionovo to Present on Novel Female Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society 14259 2Bionovo to Present on Novel Female Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society 14259 3DOR BioPharma Announces Private Equity Financing of 243 85 Million with its Partner Sigma Tau and Other Institutional Investors 5060 1DOR BioPharma Announces Private Equity Financing of 243 85 Million with its Partner Sigma Tau and Other Institutional Investors 5060 2DOR BioPharma Announces Private Equity Financing of 243 85 Million with its Partner Sigma Tau and Other Institutional Investors 5060 3DOR BioPharma Announces Private Equity Financing of 243 85 Million with its Partner Sigma Tau and Other Institutional Investors 5060 4
...University at Buffalo and the University of Pennsy...acellular events, both stimulated by the same cell...als. , The broad implication of the findings may a...t sub-cellular underpinnings of mammalian behavior...vergent Behavioral Roles of Angiotensin Receptor I...
...k-footed geese (Anser brachyrhynchus) prepare for ...n the Arctic, ecologists are warning that the esca...hreatening the birds, survival. Writing in the new... of Applied Ecology, Professor Marcel Klaassen of ...ernational action is urgently required. , Farmers ...
...x linking artificial sweeteners such as saccharin ...es on a sweet taste has guided researchers to an i...taste. , Reporting in an advance online publicat... Senses Center describe how certain artificial swe...-K, paradoxically inhibit sweet taste at high conc...
Other Biology News:Manipulating single cell receptor alters animal behavior 2Manipulating single cell receptor alters animal behavior 3Spring migration of pink-footed geese under threat 2Sweet 'water taste' paradoxically predicts sweet taste inhibitors 2
Disposable Cuvettes, 1,000/pkg from Promega
luciferase Assay Kit, Bright-Glo from Promega
... ideal for developing single and multi-analyte ass... contains the new, improved, and user friendly IS ... specific templates for commercial or home-made mu...hing and data regression capabilities; the interna...
...ified USDA Research Registered OLAW Assured AAALAC...ing AALAS Certified Technicians Documentation G...on Request Focus CRP is your one stop shopping p... We offer free project consultation, free peptide...
Biology Products: